Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension

Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension

Abstract Background Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), can reduce cardiovascular events and mortality in patients with heart failure. A number of mechanisms have been proposed to explain the beneficial effects of SGLT2 inhibitors. The purpose of this stud...

Full description

Bibliographic Details
Main Authors: Yi Tang, Siyuan Tan, Minqi Li, Yijin Tang, Xiaoping Xu, Qinghai Zhang, Qinghua Fu, Mingxiang Tang, Jin He, Yi Zhang, Zhaofen Zheng, Jianqiang Peng, Tengteng Zhu, Wenlin Xie
Format: Article
Language:English
Published: BMC 2022-04-01
Series:BMC Pulmonary Medicine
Subjects:
Dapagliflozin
Sildenafil
Pulmonary arterial hypertension
Online Access:https://doi.org/10.1186/s12890-022-01939-7

Internet

https://doi.org/10.1186/s12890-022-01939-7

Similar Items